Table 3

Symptoms of Takayasu arteritis at relapse (ITT population)

Tocilizumab subcutaneous 162 mg/week
(n=18)
Placebo
(n=18)
Patients who relapsed, n811
Patients with symptoms, n (%)*
 Systemic symptoms (objective assessment)1 (12.5)4 (36.4)
 Systemic symptoms (subjective assessment)8 (100)9 (81.8)
 Elevated inflammation marker2 (25.0)5 (45.5)
 Vascular signs and symptoms7 (87.5)9 (81.8)
 Ischaemic symptoms2 (25.0)2 (18.2)
Image evaluation, n (%)2 (25.0)1 (9.1)
  • *Percentages are based on the number of patients who relapsed.

  • ITT, intent-to-treat.